Boston Scientific (BSX) Net Cash Flow (2009 - 2026)

Boston Scientific has disclosed Net Cash Flow across 18 years of filings, most recently posting -$503.0 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$503.0 million, down 283.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $722.0 million (up 144.79% YoY), and the FY2025 annual result was $1.5 billion, up 442.24% from the prior year.
• Net Cash Flow came in at -$503.0 million for Q1 2026 at Boston Scientific, down from $668.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.4 billion in Q1 2024 to a low of -$2.0 billion in Q4 2024.
• The 5-year median for Net Cash Flow is -$66.0 million (2022), against an average of -$31.8 million.
• Across the five-year window, Net Cash Flow soared 6844.44% in 2022 and slumped 2411.11% in 2024, its largest moves.
• Boston Scientific's Net Cash Flow stood at $625.0 million in 2022, then plunged by 112.96% to -$81.0 million in 2023, then plunged by 2411.11% to -$2.0 billion in 2024, then surged by 132.84% to $668.0 million in 2025, then slumped by 175.3% to -$503.0 million in 2026.
• The last three Net Cash Flow figures came in at -$503.0 million (Q1 2026), $668.0 million (Q4 2025), and $737.0 million (Q3 2025), per Business Quant data.